{"type":"trials","record":{"id":27982,"source_id":"clinicaltrials-gov","external_id":"NCT05653258","title":"Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","brief_summary":"All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).","overall_status":"Recruiting","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Cedars-Sinai Medical Center","enrollment":160,"countries":["United States"],"start_date":"2023-10-17","completion_date":"2028-02-01","last_update_date":"2026-03-18","source_url":"https://clinicaltrials.gov/study/NCT05653258","editorial_summary":"A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:08.561263+00:00","last_seen_at":"2026-09-25T06:20:04.694+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Cedars-Sinai Medical Center","interventions":["Lifestyle Intervention","Dasatinib 100 MG","Quercetin 1000mg","Placebo","Abdominal adipose tissue biopsy"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Insulin sensitivity — Week 4 and Week 15","Glucose tolerance — Baseline to Week 14","Senescence-associated secretory phenotype (SASP) — Baseline to Week 16"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Obesity","Healthy Lifestyle","Lifestyle Intervention","Dasatinib 100 MG","Quercetin 1000mg","Placebo","Abdominal adipose tissue biopsy"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: senescent cell.","quality_checked_at":"2026-09-25T06:20:05.499352+00:00","duplicate_cluster_key":"id:nct05653258","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-10-17 to 2028-02-01","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:04.703Z","intervention":["Lifestyle Intervention","Dasatinib 100 MG","Quercetin 1000mg","Placebo","Abdominal adipose tissue biopsy"],"participants":160,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2, PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Insulin sensitivity — Week 4 and Week 15","Glucose tolerance — Baseline to Week 14","Senescence-associated secretory phenotype (SASP) — Baseline to Week 16"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"senolytics","is_published":true,"match_reasons":["Title contains controlled term: senescent cell.","Abstract contains controlled term: senolytic.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","study type"],"relevance_score":100,"intelligence_topics":{"name":"Senolytics","slug":"senolytics"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/27982","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}